featured
Cobimetinib + Chemotherapy ± Atezolizumab as First-Line Treatment for Locally Advanced or Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Randomized Trial of Cobimetinib Plus Chemotherapy, With or Without Atezolizumab, as First-Line Treatment for Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (COLET): Primary Analysis
Ann. Oncol 2021 Feb 01;[EPub Ahead of Print], A Brufsky, SB Kim, Ž Zvirbule, A Eniu, J Mebis, JH Sohn, M Wongchenko, S Chohan, R Amin, Y Yan, V McNally, D Miles, S LoiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.